



GILEAD

Advancing Therapeutics.
Improving Lives.

January 5, 2011

Ms. Sophie Delaunay
Executive Director
Doctors without Borders/Médecins sans Frontières
333 Seventh Avenue, 2nd Floor
New York, NY 10001-5004


Dear Ms. Delaunay:

Thank you for reaching out to Gilead in regard to the Medicines Patent Pool. This is an important initiative, and we are pleased to provide an update on the status of our discussions. Late last year, we entered into formal negotiations with the Medicines Patent Pool team. Over the course of these negotiations, we have consistently raised some of the critical issues that will determine our participation. We are encouraged by the concept and hope the terms will be structured in a way to accommodate our core concerns and to attract other parties beyond Gilead to join the patent pool.

As evidenced by Gilead's access model, generic licensing has been effective at expanding access to antiretroviral treatment for patients around the world by lowering prices and encouraging the development of new fixed-dose combinations and pediatric formulations. As we look toward developing the next generation of licensing agreements, we hope the patent pool will be fully operational and contribute to this shared access goal.

We appreciate your input and look forward to your future feedback.

Sincerely,



Gregg Alton
Executive Vice President, Corporate and Medical Affairs

cc: Polly Fields, Associate Director, Public Affairs
Tido von Schoen-Angerer, Executive Director, MSF Campaign for Access to Essential Medicines
Michelle Childs, Policy and Advocacy Director, MSF Campaign for Access to Essential Medicines